Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation

Diabetes and Vascular Disease Research

Volumn 9, Issue 3, 2012, Pages 163-169

  Standl, Eberhard ^a   Schnell, Oliver ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acarbose Evaluation Trial; Alpha glucosidase inhibitors; glycaemic variability; myocardial infarction; postprandial hyperglycaemia; STOP NIDDM Trial

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; MIGLITOL; VOGLIBOSE;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; POST HOC ANALYSIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

1-DEOXYNOJIRIMYCIN; ACARBOSE; ALPHA-GLUCOSIDASES; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL;

EID: 84863482399     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112441524     Document Type: Review

References (54)

1. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136. (Pubitemid 46137814)
2. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. (Pubitemid 351831356)
3. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
5. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
6. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61-68.
7. Haller H, Ito S, Izzo Jr JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
8. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
9. National Institute for Health and Clinical Excellence. Type 2 diabetes: Newer agents. NICE short clinical guideline 87. London: NICE, 2009; pp. 1-102.
10. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23: 479-484. (Pubitemid 47520905)
11. Mellbin LG, Malmberg K, Norhammar A, et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011; 54: 1308-1317.
12. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur H J 2011; 32: 1900-1908.
13. Lefebvre PJ and Standl E. New aspects in diabetes. Treatment strategies with alpha-glucosidase inhibitors. Berlin/New York: Walter de Gruyter, 1992, pp. 1-294.
14. Desai A and Tandon N. Diabetes mellitus: everyday practice. Natl Med J India 2007; 20: 192-198.
15. IMSPlus CHPA, IMS Global Services. China Hospital Pharmaceutical Audit. Quarterly Market Brief 2Q2009 and China Pharmaceutical Market Snapshot Q2/2011, www.IMSHealth.com (accessed 15 January 2012).
16. Bischoff H. Pharmacology of alpha-glucosidase-inhibitors. In: Vasselli J, Maggio C, Scriabine A (eds) Drugs in development: alpha-glucosidase inhibition: potential use in diabetes. Branford, CT, USA: Neva Press, 1993, pp. 3-13.
17. Qualmann C, Nauck MA, Holst JJ, et al. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and the lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896.
18. Göke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995; 56: 493-501.
19. Standl E, Schernthaner G, Rybka J, et al. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Res Clin Pract 2001; 52: 205-213. (Pubitemid 32223915)
20. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosdase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163. (Pubitemid 40095800)
21. Hanefeld M and Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008; 6: 153-163. (Pubitemid 351372584)
22. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441. (Pubitemid 351490110)
23. Schnell O, Chan J and Josse RG. Therapeutic experience with acarbose in the treatment of type 2 diabetes. Diabetes Metab & the Heart 2009; 18: 409-415.
24. Standl E, Schnell O and Ceriello A. Postprandial hyperglycemia and glycemic variability. Should we care? Diabetes Care 2011; 34(Suppl 2): 120-127.
25. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240. (Pubitemid 29056916)
26. The DECODE Study Group; European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnsotic criteria in Europe. Lancet 1999; 354: 617-621.
27. Nakagami T; DECODA Study Group. Hyperglycemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-394.
28. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924. (Pubitemid 29241045)
29. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157. (Pubitemid 47057520)
30. Barr EL, Boyko EJ, Zimmet PZ, et al. Continuous relationship between non-diabetic hyperglycemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009; 52: 415-424.
31. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1345-1350. (Pubitemid 351519731)
32. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study. 11 year follow-up. Diabetologia 1996; 39: 1577-1583. (Pubitemid 26397370)
33. Cavalot F, Pettrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813-819. (Pubitemid 43357744)
34. Meier JJ, Baller B, Menge BA, et al. Excess glycemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycemia and vice versa? Diabetes Obes Metab 2009; 11: 213-222.
35. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-1354.
36. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute Glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
37. Schisano B, Tripathi G, McGee K, et al. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011; 54: 1219-1226.
38. Scognamiglio R, Negut C, de Kreutzenberg SV, et al. Effect of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 2006; 29: 95-100. (Pubitemid 44033438)
39. Wascher TC, Schmoelzer I, Wiegratz A, et al. Reduction of postchallenge hyperglycemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005; 35: 551-557. (Pubitemid 41243298)
40. Shimabukuro M, Higa N, Chinen I, et al. Effects of a single administration of acarbose on post-prandial glucose excursions and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-842. (Pubitemid 43357747)
41. Bengel FM, Abletshauser C, Neverve J, et al. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus - a randomized study using positron emission tomography. Diabetic Med 2004; 22: 158-163. (Pubitemid 40204321)
42. Miyamura M, Schnell O, Yamashita C, et al. Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice. J Pharmacol Sci 2010; 114: 32-40.
43. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077. (Pubitemid 34680970)
44. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impairedglucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494. (Pubitemid 37430502)
45. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 25: 10-16.
46. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16. (Pubitemid 38055587)
47. Rosenthal JH and Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and typ 2 diabetes mellitus. Clin Drug Invest 2002; 22: 695-701. (Pubitemid 35155504)
48. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomized, double-blind tiral in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-1614.
49. Holman RR, Haffner SM, McMurray JJ, et al. NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-1476.
50. Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia On cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32: 381-386.
51. Acarbose Cardiovascular Evaluation, launched 11 April 2008. http//www.dtu.ox.ac.uk/ace/index (accessed 15 December 2011).
52. Li C, Hung Y-J, Qamruddin K, et al. International Noninterventional study of acarbose treatment in patients with typ 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 92: 57-64.
53. Lin S-D, Wang J-S, Hsu S-R, et al. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared withsulfonyurea in Taiwanese type 2 diabetic patients inadequatelycontrolled with metformin: Preliminary data. J Diabet Complications. Epub ahead of print 1 August 2011, DOI: 10.1016/j.jdiacomp. 2011.06.004.
54. Schnell O, Mertes G and Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 6: 853-858. (Pubitemid 47555206)